Tag: Hypertrophic cardiomyopathy

Beta-blockers like propranolol have been used as a primary medical therapy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) since studies in the 1960s confirmed their benefits. This makes it clear that propranolol is not contraindicated in HOCM, but rather a long-standing treatment option to manage symptoms.

Hypertrophic cardiomyopathy (HCM) affects an estimated 1 in 500 people, though some genetic data suggests the prevalence could be as high as 1 in 200 [1.5.4, 1.8.5]. Historically, treatments only managed symptoms. So, *what is the new medication for hypertrophic cardiomyopathy* that offers a targeted approach?

Over 1.5 million Americans are affected by symptomatic spinal stenosis, but for the condition as a whole, there is no singular **what is the drug of choice for stenosis?**. The answer is complex because "stenosis" refers to any abnormal narrowing of a vessel or opening, meaning medication depends entirely on the location and cause of the narrowing.